Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 2, 2008, Pages 459-464

  Azuma, Koichiro ^a   Rádiková, Zofia ^a   Mancino, Juliet ^a   Toledo, Frederico G S ^a   Thomas, Ernestine ^a   Kangani, Cyrous ^a   Dalla Man, Chiara ^b   Cobelli, Claudio ^b   Holst, Jens J ^c   Deacon, Carolyn F ^c   He, YanLing ^d   Ligueros Saylan, Monica ^e   Serra, Denise ^e   Foley, James E ^e   Kelley, David E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NOVARTIS PHARMA K K   (Japan)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; POLYPEPTIDE; VILDAGLIPTIN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; INSULIN INFUSION; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 39049141231     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1369     Document Type: Article

References (31)

1. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
2. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266
3. Egan JM, Clocquet AR, Elahi D 2002 The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87:1282-1290
4. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D 2001 Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956
5. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
6. Ahren B, Larsson H, Holst JJ 1997 Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478
7. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA 2000 Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49:611-617
8. Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA 2002 Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia 45:1410-1415
9. Drucker DJ 2003 Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940
10. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888-4894
11. Ahren B, Landin-Olsson M, Jansson PA, Svenson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
12. Ahren B, Pacini G, Foley JE, Schweizer A 2005 Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1year. Diabetes Care 28:1936-1940
13. Brazg R, Xu L, Dalla MC, Cobelli C, Thomas K, Stein PP 2007 Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9:186-193
14. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249-1255
15. He YL, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE, Wang Y 2007 Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47:633-641
16. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
17. Shah P, Basu A, Basu R, Rizza R 1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283-E290
18. 1c over one year in drug-naive patients with type 2 diabetes. Diabet Med 24:955-961
19. Woerle HJ, Lindenberger T, Linke R, Foley JE, Ligueros-Saylan MA, Zang Y, He YL, Beglinger C, Goeke B, Schirra J 2007 A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes (T2DM). Diabetes 56:A133 (Abstract)
20. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Ligueros SM, Dunning BE, Foley JE, Rizza RA, Camilleri M 2007 Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480
21. Vinik A, Pittenger G, Rafaeloff R, Rosenberg L 1992 Factors controlling pancreatic islet neogenesis. Yale J Biol Med 65:471-491
22. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
23. Dole VP, Meinertz H 1960 Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 235:2595-2599
24. Wolfe RR 1992 Radioactive and stable isotope tracers in bio-medicine: principles and practice of kinetic analysis. New York: Wiley-Liss
25. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C 2001 Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity. Diabetes 50:150-158
26. Wolfe RR, Chinkes DL 2005 Isotope tracers in metabolic research: principles and practice of kinetic analysis. 2nd ed. New York: John Wiley, Sons
27. Frayn KN 1983 Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634
28. Yki-Jarvinen H 2004 Glucose toxicity. New York: John Wiley, Sons
29. Matthaei S, Stumvoll M, Kellerer M, Haring HU 2000 Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585-618
30. Natali A, Ferrannini E 2006 Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434-441
31. Migoya EM, Miller J, Larson P, Tanes M, Hilliard D, Deacon C, Guitierrez M, Stoch A, Herman GA, Stein PP, Holst JJ, Wagner JA 2007 Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetes 56:A74 (Abstract)